New Cell Therapy Saves Lives of Liver Disease Patients

Scientists in Scotland just proved that your own blood cells can be turned into a treatment that reverses liver failure. The breakthrough offers real hope for the 11,000 people who die each year in the UK from advanced liver disease when transplants aren't available.

Researchers at The University of Edinburgh developed a therapy that takes immune cells from a patient's blood and transforms them into specialized macrophages. These souped-up white blood cells act like tiny cleanup crews, eating away scar tissue and coaxing healthy liver cells to grow back.

The treatment tackles cirrhosis, the severe scarring that leaves livers damaged beyond natural repair. More than three-quarters of people are diagnosed with cirrhosis too late for effective treatment, and transplants can only help a small fraction due to limited donor organs, high costs, and strict eligibility requirements.

In the MATCH clinical trial, 26 patients received the new macrophage therapy while 24 got standard care. The results were remarkable: after four years, 70% of patients who received the cell therapy were alive without needing a transplant, compared to just 40% of those who got standard care alone.

The therapy group saw eight deaths and zero transplants, while the standard care group had nine deaths and five transplants. No serious side effects appeared in the patients treated with the cell therapy, proving both its safety and effectiveness over the long term.

The Ripple Effect

This breakthrough means fewer families will hear the devastating news that a transplant is their only hope and one may never come. Every patient who responds to this therapy is one less person on the transplant waiting list, improving odds for those who still need a donor organ.

Resolution Therapeutics, the company founded to bring this science to patients, is already testing an improved version called RTX001 in a new trial called EMERALD. The therapy could transform liver disease from a death sentence into a manageable condition.

Stuart Forbes, who led the research at Edinburgh's Institute for Regeneration and Repair, says the approach could one day add crucial treatment choices for patients with advanced liver disease. The work took over a decade of collaboration between the university, the Scottish National Blood Transfusion Service, and patient advocates who shaped the research from the beginning.

For people living with cirrhosis, these results deliver something that's been missing for too long: real hope that doesn't depend on winning the transplant lottery.